Bromelains is a Enzyme owned by MediWound, and is involved in 15 clinical trials, of which 13 were completed, and 2 are ongoing.
Bromelain is a debridement agent which contains mixture of enzymes that digest protein. The drug candidate has fibrinolytic and proteolytic activity by which it facilitates the reabsorption of hematic effusions. The proteolytic enzymes present in the drug candidate act by dissolving the burn wound eschar (dead and damaged tissues) without harming the healthy tissues which may prove to be effective in treating the disease condition.
The revenue for Bromelains is expected to reach a total of $509m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bromelains NPV Report.
Bromelains (NexoBrid) is a protein extract derived from the stems of Pineapples, Ananas comosus. It is formulated as powder and gel for cutaneous route of administration. It is indicated for removal of eschar in adults with deep partial and full-thickness thermal burns.
The drug candidate is under development for the treatment of severe burns, sulfur mustard (chemical warfare agent) injuries in the U.S., EU, Japan and India. The development of the drug candidate is based on proteolytic enzymatic technology.
Vericel develops and markets advanced cell therapies for sports medicine and severe burn care domain. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts for skin replacement. It also holds an exclusive license for NexoBrid in North America for the treatment of severe thermal burns. Vericel has manufacturing facility in Cambridge, Massachusetts and sells its products to sports medicine orthopedic surgeons and specialized burn centers through cell therapy specialists in the US. Vericel is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$156.2 million for the fiscal year ended December 2021 (FY2021), an increase of 25.8% over FY2020. The operating loss of the company was US$7.9 million in FY2021, compared to an operating profit of US$2.4 million in FY2020. The net loss of the company was US$7.5 million in FY2021, compared to a net profit of US$2.9 million in FY2020. The company reported revenues of US$38.6 million for the third quarter ended September 2022, an increase of 4.1% over the previous quarter.
Quick View – Bromelains
|Highest Development Stage|